76 related articles for article (PubMed ID: 24720908)
1. A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol.
Koka A; Saygin C; Uzunaslan D; Ozdemir N; Apak H; Celkan T
Leuk Res; 2014 Jun; 38(6):699-705. PubMed ID: 24720908
[TBL] [Abstract][Full Text] [Related]
2. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
3. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).
Kamps WA; Bökkerink JP; Hakvoort-Cammel FG; Veerman AJ; Weening RS; van Wering ER; van Weerden JF; Hermans J; Slater R; van den Berg E; Kroes WG; van der Does-van den Berg A
Leukemia; 2002 Jun; 16(6):1099-111. PubMed ID: 12040440
[TBL] [Abstract][Full Text] [Related]
4. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
[TBL] [Abstract][Full Text] [Related]
9. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
10. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
11. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
12. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
Hazar V; Karasu GT; Uygun V; Akcan M; Küpesiz A; Yesilipek A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e317-22. PubMed ID: 20930649
[TBL] [Abstract][Full Text] [Related]
13. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.
Kamps WA; van der Pal-de Bruin KM; Veerman AJ; Fiocco M; Bierings M; Pieters R
Leukemia; 2010 Feb; 24(2):309-19. PubMed ID: 20016528
[TBL] [Abstract][Full Text] [Related]
16. Childhood acute lymphoblastic leukemia in Nicaragua: long-term results in the context of an international cooperative program.
Pacheco C; Lucchini G; Valsecchi MG; Malta A; Conter V; Flores A; Biondi A; Tognoni G; Arguello M; Cavalli F; Silvestri D; Lacayo FB; Masera G
Pediatr Blood Cancer; 2014 May; 61(5):827-32. PubMed ID: 24376241
[TBL] [Abstract][Full Text] [Related]
17. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M
Leukemia; 2010 Feb; 24(2):265-84. PubMed ID: 20010625
[TBL] [Abstract][Full Text] [Related]
19. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Qin J; Wollner N
Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
[TBL] [Abstract][Full Text] [Related]
20. [Long-term follow-up of 2 therapeutic programs for the treatment of high-risk childhood acute lymphoblastic leukemia. Experience at the 20 de Noviembre National Medical Center].
de Diego-Floreschapa J; López-Hernández M; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
Gac Med Mex; 1999; 135(3):253-8. PubMed ID: 10425822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
